Menu Search
Equities

Shanghai Fosun Pharmaceutical Group Co Ltd

08HH:MUN

Shanghai Fosun Pharmaceutical Group Co Ltd

Actions
  • Price (EUR)1.79
  • Today's Change-0.002 / -0.11%
  • Shares traded--
  • 1 Year change-17.82%
  • Beta--
Data delayed at least 15 minutes, as of Nov 06 2024 07:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Shanghai Fosun Pharmaceutical Group Co Ltd is a China-based company mainly engaged in the research and development, manufacturing and sales of pharmaceutical products. The Company operates in five segments. Pharmaceutical segment is mainly engaged in the manufacturing of innovative drugs, mature pharmaceutical products and vaccines. Medical Devices and Medical Diagnostics segment is mainly engaged in the manufacturing and sales of medical cosmetic devices such as molecular diagnosis, immunodiagnosis, and microbial diagnosis. Medical Health Services segment is mainly engaged in the operation of an online and offline integrated medical service platform. Pharmaceutical Distribution and Retail segment is mainly engaged in the wholesale and retail of pharmaceutical products. Others segment is engaged in other pharmaceutical-related businesses. The Company's products are mainly used in the treatment of tumors, immunity, central nervous system and other fields.

  • Revenue in HKD (TTM)44.14bn
  • Net income in HKD2.01bn
  • Incorporated1995
  • Employees39.31k
  • Location
    Shanghai Fosun Pharmaceutical Group Co LtdBuilding A, No. 1289 Yishan RoadSHANGHAI 200233ChinaCHN
  • Phone+86 2 133987870
  • Fax+86 2 133987871
  • Websitehttps://www.fosunpharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.